Allergan To Acquire KYTHERA Biopharma For $75 Per KYTHERA Share - Quick Facts

(RTTNews) - Allergan plc (AGN) and KYTHERA Biopharmaceuticals, Inc. (KYTH) announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity  transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.

The fixed-value transaction consideration will be payable 80 percent in cash and 20 percent in new AGN shares issued to KYTHERA shareholders.

Allergan's 2015 earnings-per-share forecast provided on May 11, 2015 is unchanged as a result of the acquisition. The acquisition is expected to be breakeven in 2016 and accretive thereafter.

The acquisition of KYTHERA immediately enhances Allergan's global facial aesthetics portfolio with the addition of KYBELLA injection, the first and only approved non-surgical treatment for contouring moderate to severe submental fullness, commonly referred to as double chin.

KYTHERA is executing a training-led launch in the U.S. supported by a training program designed to educate physicians and qualified injectors on the safe use of KYBELLA and its approved indication. Physician faculty education in the U.S. began in June 2015.

Allergan currently anticipates closing the transaction in the third quarter of 2015.